A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of VBP-245 in Pediatric Subjects for the Treatment of Molluscum Contagiosum
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs VBP 245 (Primary)
- Indications Molluscum contagiosum
- Focus Therapeutic Use
- Sponsors Veloce BioPharma
- 31 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Jun 2018.
- 31 Jan 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Mar 2018.
- 31 Jan 2018 Status changed from recruiting to active, no longer recruiting.